Shots: The approval is based on P-III JAVELIN Bladder 100 study assessing Bavencio (10 mg/kg, IV infusion, q2w) + BSC vs BSC as monothx. in 700 patients with LA/ m-UC […]readmore
Tags : Bavencio
Shots: The EMA has validated the type II variation application for Bavencio which is based on P-III JAVELIN Bladder 100 study assessing Bavencio +BSC vs BSC as monothx. in 700 […]readmore
Shots: The P-II study involves assessing of Bavencio in 15 women (median age 34yrs.) with GTT that are resistant to mono-CT. All patients had progressed on treatment with MTX; one […]readmore
Shots: The companies have completed the submission of sBLA to the US FDA as 1L maintenance therapy for patients with LA/m-UC and have received FDA’s BT designation for the same […]readmore
Shots: The P-III JAVELIN Head and Neck 100 study involve assessing of Bavencio (avelumab) + CRT followed by avelumab maintenance vs CRT alone in 697 patients with previously untreated LA […]readmore
Shots: The P-III JAVELIN Bladder 100 study involves assessing of Bavencio + best supportive care (BSC) vs BSC monothx in 700 patients with LA or mUC whose disease did not […]readmore
Shots: The approval is based in P-III JAVELIN Renal 101 study assessing Bavencio + Axitinib vs Sunitinib in 886 patients with untreated advanced or metastatic RCC with all IMDC prognostic […]readmore
Shots: The approval is based on P-III JAVELIN Renal 101 study (NCT02684006) results assessing bavencio (avelumab) + Inlyta (axitinib) vs sunitinib in 886 patients in a ratio (1:1) with untreated […]readmore
Shots: The P-III JAVELIN Renal 101 trial involves assessing of Bavencio (avelumab) + Inlyta (axitinib) vs Sutent (sunitinib) in 886 patients with previously untreated advanced RCC P-III JAVELIN Renal 101 […]readmore